EBC - ON DEMAND
Resolute pooled data in bifurcation lesions
European Bifurcation Club 2011, EBC 2011 – Lisbon, Portugal
HOT NEWS SESSION
Resolute pooled data in bifurcation lesions
Author: Ran Kornowski, MD, Rabin Medical Center and Tel Aviv University, Israel
BACKGROUND
- Bifurcation lesions remain a therapeutic challenge and a focus of great interest among interventional cardiologists.
- The impact of the Resolute DES platform, with its open-cell design and unique BioLinxpolymer and Zotarolimus anti-proliferative drug, on the technical and clinical outcomes in bifurcation lesions has not been yet explored.
CONCLUSION
In the pooled dataset with Resolute bifurcation lesions we observed:
- Excellent technical/angiographic success rate with 19.1% need for SB stenting in the treated cohort.
- Sustainable clinical efficacy out to one year(e.g.very low rates of TLR 4.8% and TVR 6.1%).
- Favorable TLF (10.3%) event rate with low stent thrombosis (2.0%, mostly early) up to one year.
- Thus, the Resolute DES platform is a viable treatment option for bifurcation lesion management.